



# Sustained-drug release: A future non-drop alternative in interventional glaucoma

An AbbVie-sponsored symposium at the  
 42nd ESCRS Congress

9 September 2024 | 13:00–14:00 CEST

Room 8.0 A, Fira de Barcelona  
 Barcelona, Spain

Join us for this exciting symposium at  
 ESCRS Congress 2024 to explore the  
 potential of non-drop therapeutic options  
 in glaucoma, as we discuss:




Challenges associated with traditional  
 glaucoma drop therapy



Emerging data from clinical trial programmes  
 investigating sustained drug delivery



Mechanisms by which sustained-release implants  
 may achieve prolonged duration of effect



**Dr Marta Pazos**  
 Hospital Clínic de Barcelona,  
 University of Barcelona, Spain



**Professor Miriam Kolko**  
 University of Copenhagen, Denmark



**Dr I. Paul Singh**  
 The Eye Centers of Racine and Kenosha,  
 USA



**Dr Andrew Tatham**  
 Princess Alexandra Eye Pavilion,  
 Edinburgh, UK

Topic	Presenter/Moderator
Welcome and introductions	Chair: Dr Marta Pazos, Spain
Glaucoma drops and the ocular surface	Professor Miriam Kolko, Denmark
Sustained drug delivery: Update on clinical programmes	Dr I. Paul Singh, USA
Mode of action for the sustained effect of prostaglandins	Dr Andrew Tatham, UK
Q&A and close	All, moderated by Dr Marta Pazos

This non-promotional, medical educational event is organised and funded by AbbVie. In relation to the invitation to the event, we inform you that it is personal in nature and its content is aimed exclusively at Healthcare Professionals. Actions aimed at reproducing its content, in whole or in part, altering it or using it for other purposes, as well as forwarding it to third parties, are not permitted without the prior consent of AbbVie. The presentations and materials disseminated at the event are subject to intellectual property rights, so their use or reproduction requires prior authorisation from AbbVie. Furthermore, in order to comply with the regulations regarding the promotion of medicines, we ask you not to share its contents on your social networks. Please do not distribute in media, media or communication channels aimed at the general public. ABBV-AA-03544-E | V1.0 July 2024